AnalysisNews

ZEAL today

Trend

—

Key levels

—

Latest news & SEC filings

ProductNov 13, 2026Zealand Pharma secures European approval for its drug Zeydovio (glepaglutide)

ProductNov 13, 2026Zealand Pharma receives EU marketing authorization for Zeydovio in short bowel syndrome

DealNov 12, 2026Zealand Pharma restarts glepaglutide partnering discussions, CFO says

EarningsNov 12, 2026Zealand Pharma posts financial results for 2026 period ending in September

All ZEAL news →

N/A · N/A

ZEAL (ZEAL)

$0.00+0.00 (+0.00%)
Risk: LOW

What Is the Price Target for ZEAL?

SEPT Low Target

$0.00

SEPT Mid Target

$0.00

SEPT High Target

$0.00

Analyst Consensus

$0.00

Current: $0.00Upside: +0.0%Confidence: 20%Method: No Coverage

Is ZEAL a Buy or Sell Right Now?

0
Investability Score
12-18 months
News summary · last 30 days
Nov 13▲ UpFda2 articles
Zealand Pharma secured European Commission approval for its drug Zeydovio (glepaglutide), a long-acting next-generation GLP-2 analog for treating adults with short bowel syndrome. This regulatory clearance allows the company to begin selling the treatment across European countries. The news is a significant positive catalyst for the stock, as it opens a new commercial market for the company's product. The bullish sentiment and high impact suggest upward pressure on ZEAL shares.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ZEAL.

Start Free Trial →

Is ZEAL Overvalued or Undervalued?

Valuation Verdict

N/A

Methods Used

N/A

Fair Value

$N/A

0

Moat Score

NONE

0/9

Piotroski Score

N/A

Altman Z-Score

What Is Smart Money Doing with ZEAL?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

ZEAL Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

N/A

FCF Growth YoY

N/A%

Revenue Trend

UNKNOWN

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for ZEAL (ZEAL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...

Sign Up Free — Download AI Report PDF →

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

Compare SEPT with other platforms

SEPT vs TradingViewSEPT vs BloombergSEPT vs Unusual WhalesSEPT vs SpotGammaSEPT vs TrendSpiderAI Trading Platforms Compared
What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

About SEPT Investing

SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

ZEAL — frequently asked questions

Why is ZEAL stock moving today?

Latest ZEAL news — Nov 13, 2026: Zealand Pharma secures European approval for its drug Zeydovio (glepaglutide) · Nov 13, 2026: Zealand Pharma receives EU marketing authorization for Zeydovio in short bowel syndrome

Why did ZEAL stock move on Nov 13, 2026?

Zealand Pharma secured European Commission approval for its drug Zeydovio (glepaglutide), a long-acting next-generation GLP-2 analog for treating adults with short bowel syndrome. This regulatory clearance allows the company to begin selling the treatment across European countries.

What are insiders doing with ZEAL?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on ZEAL?

Nov 13, 2026: Zealand Pharma secures European approval for its drug Zeydovio (glepaglutide) · Nov 13, 2026: Zealand Pharma receives EU marketing authorization for Zeydovio in short bowel syndrome · Nov 12, 2026: Zealand Pharma restarts glepaglutide partnering discussions, CFO says